This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information
Efficacy & SafetyAboutEfficacy & SafetyPatient SupportAboutAboutCommitment to the GH CommunityIndication & DosingIndication & DosingAdultsChildren

Menu

Close

Efficacy & SafetyAdultAdult Growth Hormone DeficiencyChildrenSmall for Gestational AgeTurner SyndromePrader-Willi SyndromeChronic Renal Insufficiency
Pediatric Growth Hormone Deficiency
Idiopathic Short Stature
DevicesPenPen PresentationHow to Use the PenGoQuickGoQuick PresentationHow to Use GoQuickPatient SupportPatient SupportGroAssistBranded Patient Information LeafletsEducational SupportEducational SupportPrescribing InformationWebinarsEventsMaterialsVideos
ChildrenChiChiAdultC

Paediatric Growth Hormone Deficiency

Genotropin® has proven efficacy in PGHD1 for achievement of genetic height potential2

   

Genotropin® is effective in treating idiopathic PGHD2

   

   

Adapted from Cutfield W, et al. 1999.2

   

Study methods2

   

An analysis of the final height in idiopathic GHD patients enrolled in the KIGS database was performed. Of the 10,657 idiopathic GHD patients enrolled from 43 participating countries, 369 fulfilled the necessary final height criteria for inclusion in the analysis and were treated on an average dose of 0.49 IU/kg body weight/week (0.16 mg/kg body weight/week) GH for a median of 8.1 years. A Swedish subgroup of patients (n=69) received conventional therapy (0.65 IU/kg body weight/week) for a mean of 9.4 years. The criteria used to define the final height were height velocity less than 2 cm/year, calculated over a minimum period of 9 months; chronological age greater than 17 years or bone age greater than 16 years in boys; chronological age greater than 15 years or bone age greater than 14 years in girls. To be included in the analysis, the children had to have more than 2 years of GH treatment prior to puberty and more than 5 years of GH treatment in total.

   

Safety3

Adverse events in the long-term treatment of children with GHD

   

Adapted from Genotropin. Local product document. 2022. LPDSOM052020.

   

   

*Reported in growth hormone deficient children treated with somatropin, but the incidence appears to be similar to that in children without growth hormone deficiency.
In general, these adverse effects are mild to moderate, arise within the first months of treatment, and subside spontaneously or with dose-reduction. The incidence of these adverse effects is related to the administered dose, the age of the patients, and possibly inversely related to the age of the patients at the onset of growth hormone deficiency.
Transient injection site reactions in children have been reported.
§Clinical significance is unknown.

   

ADR, adverse drug reaction; BMI, body mass index; GH, growth hormone; GHD, growth hormone deficiency; KIGS, Kabi International Growth Study; PWS, Prader-Willi syndrome; PGHD, paediatric growth hormone deficiency; SD, standard deviation; SDS, standard deviation score.

   

References:

Genotropin. Local product document. Pfizer; 2022. Version LPDSOM052020.Cutfield W, Lindberg A, Wikland KA, Chatelain P, Ranke MB, Wilton P. Final height in idiopathic growth hormone deficiency: the KIGS experience. KIGS International Board. Acta Paediatr Suppl. 1999;88(428):72-75.

   

PP-GEN-IND-0678 July 2022

Devices

Simplicity and flexibility in administration1

Learn moreLoading
Children

   

Devices

Simplicity and flexibility in administration1

Learn moreLoading
Patient Support

Multiple support material

Learn moreLoading
Educational Support

Review the upcoming events

Learn moreLoading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-GEN-IND-0678

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​